Delayed Treatment with Brelovitug

Phase 3Small molecule

Delayed Treatment with Brelovitug is one of 27 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis D InfectionActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Chronic Hepatitis D InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 3

Delayed Treatment with Brelovitug

MMirum Pharmaceuticals, Inc.

Phase 3

1 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Active, not recruiting

Chronic Hepatitis D Infection

NCT07298330

Q3 2029

Phase 2/3Active, not recruiting

Chronic Hepatitis

NCT06907290

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

Active, not recruiting·MMirum Pharmaceuticals, Inc.·Phase 2/3·NCT06907290·150 enrolled

Chronic Hepatitis D Infection1 trial

A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Active, not recruiting·MMirum Pharmaceuticals, Inc.·Phase 3·NCT07298330·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Delayed Treatment with Brelovitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Delayed Treatment with Brelovitug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Delayed Treatment with Brelovitug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirum Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMirum Pharmaceuticals, Inc.

Delayed Treatment with Brelovitug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Trials by Indication[1]

Chronic Hepatitis1 trial

Chronic Hepatitis D Infection1 trial

References

Drug Info

Quick Facts

Related News